Valuation: UCB

Market Cap 43.13B 49.77B 40.37B 36.84B 69.32B 4,747B 70.49B 473B 185B 2,376B 187B 183B 7,926B P/E 2026 *
22.7x
P/E 2027 * 18.6x
Enterprise Value 43.34B 50.01B 40.57B 37.02B 69.67B 4,770B 70.84B 476B 186B 2,388B 188B 184B 7,965B EV / Sales 2026 *
5x
EV / Sales 2027 * 4.26x
Free-Float
61.59%
Yield 2026 *
0.64%
Yield 2027 * 0.66%
1 day-1.31%
1 week-0.27%
Current month+2.57%
1 month-6.26%
3 months-4.49%
6 months-17.11%
Current year-4.98%
1 week 222.1
Extreme 222.1
229.2
1 month 217.7
Extreme 217.7
255.4
Current year 217.7
Extreme 217.7
285.4
1 year 187.5
Extreme 187.5
285.4
3 years 65.68
Extreme 65.68
285.4
5 years 65.68
Extreme 65.68
285.4
10 years 55.45
Extreme 55.454
285.4
Manager TitleAgeSince
Chief Executive Officer 67 01/01/2015
Director of Finance/CFO 60 01/07/2020
Chief Tech/Sci/R&D Officer 59 01/05/2024
Director TitleAgeSince
Director/Board Member 55 01/01/2012
Director/Board Member 67 01/01/2015
Director/Board Member 56 24/04/2014
Change 5-day change 1-year change 3-year change Capi.($)
-1.51%-0.27% - - 49.77B
-1.37%+4.78%+45.99%-1.23% 79.58B
+2.55%+9.01%+1.40%+30.65% 52.73B
-1.81%-2.88%+19.01%+171.00% 49.77B
+0.08%+5.95%-47.62%-47.36% 46.77B
-1.56%-2.19%+59.29%-25.50% 30.13B
-0.39%+0.39%+52.89%+83.63% 24.54B
+1.27%+6.28%+137.81%-40.32% 24.18B
0.00%+5.81%+9.45%+194.91% 21.2B
-1.15%+1.99%+73.51%+169.39% 16.36B
Average -0.64%+4.23%+39.08%+59.46% 38.36B
Weighted average by Cap. -0.58%+4.49%+29.75%+43.52%

Financials

2026 *2027 *
Net sales 8.67B 10.01B 8.12B 7.41B 13.94B 955B 14.17B 95.2B 37.3B 478B 37.58B 36.76B 1,594B 9.68B 11.17B 9.06B 8.27B 15.56B 1,066B 15.83B 106B 41.65B 533B 41.95B 41.04B 1,780B
Net income 1.89B 2.18B 1.77B 1.61B 3.03B 208B 3.08B 20.71B 8.11B 104B 8.17B 7.99B 347B 2.35B 2.71B 2.2B 2B 3.77B 258B 3.83B 25.75B 10.09B 129B 10.16B 9.94B 431B
Net Debt 213M 246M 200M 182M 343M 23.49B 349M 2.34B 918M 11.76B 925M 905M 39.23B -1.9B -2.2B -1.78B -1.63B -3.06B -209B -3.11B -20.89B -8.18B -105B -8.24B -8.06B -350B
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
12/08/26 223.30 -0.98% 82
11/08/26 €225.50 -0.04% 300
10/08/26 €225.60 +0.80% 300
07/08/26 €223.80 -2.36% 0
06/08/26 €229.20 +2.37% 0
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
226.20EUR
Average target price
286.00EUR
Spread / Average Target
+26.44%

Quarterly revenue - Rate of surprise